English

                                        
CURRICULUM VITAE (CV)
Shilan Mozafari
 
 
    
 
 
 
 
 
 
 
 
Personal
Gender: Female
Date of birth: 1986
Nationality: Iranian
Language skills: English, Persian
Education
·   Tehran University of Medical Sciences (TUMS), School of pharmacy, Tehran, Iran: Pharm D (2004-2010)
Professional Experience
Worked as:
·   Responsible pharmacist in several pharmacies (both academic and personal) in Tehran (2008- 2010)
·   DPIC expert in Iranian National DPIC (Drug and Poison Information Center) (2010)
·   Supervising manager of drug and narcotics in vice chancellor of food and drug in KUMS (Kurdistan University of Medical Sciences) (2010-2012)
·   Responsible pharmacist in personal pharmacies in Sanandaj (2010- 2012)
·   Post doctoral researcher at Pharmaceutical Sciences Research Center, TUMS (Tehran University of Medical Sciences), under supervision of Prof. Mohammad Abdollahi and BMN (National Elites Foundation) (2012-2014)
·   Co-worker at Iran's drug selecting committee in IFDA (Food and Drug Administration of the Islamic republic of Iran) (2014-present).
·   Co worker in medical and access department of Tadbir Kalay-e Jam importer company (2014-present)
·   Supervising manager of drug and narcotics in vice chancellor of food and drug in KUMS (Kurdistan University of Medical Sciences) (2014-present)
·   Owner and responsible pharmacist in my personal pharmacy (2014-present)
·   Member of health system research (HSR) committee in vice chancellor of food and drug in KUMS (2014- present)
·   Member of rational drug use (RUD) committee in vice chancellor of food and drug in KUMS (2014- present)
 
 
Professional Memberships
- Iranian Society of Pharmacy Doctors
- Medical Council, I.R. IRAN (M.C. NO: 15233)
 
Research Experience
-    Research Assistant: Faculty of Pharmacy and Pharmaceutical Sciences Research Center, TUMS (Tehran University of Medical Sciences), under supervision of Prof. Mohammad Abdollahi
-    Post doctoral researcher at Pharmaceutical Sciences Research Center, TUMS (Tehran University of Medical Sciences), under supervision of Prof. Mohammad Abdollahi and BMN (National Elites Foundation) (2012-2014)
 
Research Interests
·   Outcomes research
·   Evidenced based medicine
·   Meta-analysis
·   Systematic review
·   Comparative efficacy
·   New drug evaluation (safety and efficacy) in gastrointestinal disorders
·   Irritable bowel syndrome
·   Inflammative bowel disease
·   Oxidative stress
·   Melatonin
 
International Conferences
Active participants at International Society of Pharmacoeconomics and outcomes research (ISPOR) conference: attenuated the ISPOR 6th Asia-Pacific conference (6-9 Sep 2014. Beijing, China)
Poster presenter at the ISPOR 6th Asia-Pacific conference (6-9 Sep 2014. Beijing, China):
Pregnancy outcomes in women with inflammatory bowel disease following exposure to thiopurines and antitumor necrosis factor drugs A systematic review with meta-analysis.”
Workshops and courses certifications
Workshops
· Research methods in pharmaceutical science (2008, Pharmaceutical sciences research center of TUMS).
· Scientific writing (2008, Pharmaceutical sciences research center of TUMS).
· Handling laboratory animals (2013, Pharmaceutical sciences research center of TUMS).
· Cord blood hematopoietic stem cells (2013, Pharmaceutical sciences research center of TUMS).
· Embryonic stem cells (2013, Pharmaceutical sciences research center of TUMS).
· Tissue engineering (2013, Pharmaceutical sciences research center of TUMS).
· Bioinformatics (2013, Pharmaceutical sciences research center of TUMS).
· Gene expression analysis by RT-PCR and Real Time PCR (2013, Pharmaceutical sciences research center of TUMS).
· Gene manipulation and cloning (2013, Pharmaceutical sciences research center of TUMS).
· Flow cytometry (2013, Pharmaceutical sciences research center of TUMS).
· Immunocytochemistry and immunohistochemistry (2013, Pharmaceutical sciences research center of TUMS).
· Gene transfection to mammalian cells (2013, Pharmaceutical sciences research center of TUMS).
· Lentiviral vectors (2013, Pharmaceutical sciences research center of TUMS).
· Quality management in biomedical sciences (2013, Pharmaceutical sciences research center of TUMS).
· Scientific writing -professional (2013, Pharmaceutical sciences research center of TUMS).
Short courses
· Health economics for non-health economists (2014, C.E.L (Centre for Executive Leadership) for pharma. Brussels).
· Cost effectiveness analysis alongside clinical trials (2014 ISPOR short courses, Beijing).
· Statistical considerations in health economic evaluation (2014 ISPOR short courses, Beijing).
· Network meta-analysis and indirect treatment comparisons (2014 ISPOR short courses, Beijing).
 
Publications
According to Google Scholar (19 July 2016):
Citations: 374
h-index: 11
i10-index: 12
 
1.      Inflammatory bowel disease therapies discontinued between 2009 and 2014. Mozaffari S, Nikfar S, Abdollahi M. Expert Opin Investig Drugs. 2015;24(7):949-56. doi: 10.1517/13543784.2015.1035432. Epub 2015 Apr 10. Review.
 
2.      Effectiveness of probiotics in irritable bowel syndrome: Updated systematic review with meta-analysis. Didari T, Mozaffari S, Nikfar S, Abdollahi M. World J Gastroenterol. 2015 Mar 14;21(10):3072-84. doi: 10.3748/wjg.v21.i10.3072. Review.
 
3.      Pregnancy outcomes in women with inflammatory bowel disease following exposure to thiopurines and antitumor necrosis factor drugs: A systematic review with meta-analysis. Mozaffari S, Abdolghaffari AH, Nikfar S, Abdollahi M. Hum Exp Toxicol. 2015 May;34(5):445-59. doi: 10.1177/0960327114550882. Epub 2014 Nov 5.
 
4.      Beneficial effect of butyrate, Lactobacillus casei and L-carnitine combination in preference to each in experimental colitis. Moeinian M, Ghasemi-Niri SF, Mozaffari S, Abdolghaffari AH, Baeeri M, Navaea-Nigjeh M, Abdollahi M. World J Gastroenterol. 2014 Aug 21;20(31):10876-85. doi: 10.3748/wjg.v20.i31.10876.
 
5.      Phase II drugs under clinical investigation for the treatment of chronic constipation. Mozaffari S, Didari T, Nikfar S, Abdollahi M. Expert Opin Investig Drugs. 2014 Nov;23(11):1485-97. doi: 10.1517/13543784.2014.932770. Epub 2014 Jun 24. Review.
 
6.      Efficacy and tolerability of renzapride in irritable bowel syndrome: a meta-analysis of randomized, controlled clinical trials including 2528 patients. Mozaffari S, Nikfar S, Abdollahi M. Arch Med Sci. 2014 Feb 24;10(1):10-8. doi: 10.5114/aoms.2014.40729. Epub 2014 Feb 23. Review.
 
7.      Induction of Inflammatory Bowel Disease Through Activation of Immune System Against Enteric Bacteria H Esmaily, Y Sanei, A Asadi-Shahmirzadi, S Mozaffari, M Baeeri, .Journal of Gastroenterology and Hepatology Research 3 (2)  02/2014.
 
 
8.      The safety of novel drugs used to treat irritable bowel syndrome. Mozaffari S, Nikfar S, Abdollahi M. Expert Opin Drug Saf. 2014 May;13(5):625-38. doi: 10.1517/14740338.2014.902932. Epub 2014 Mar 26. Review.
 
9.      New biologic therapeutics for ulcerative colitis and Crohn's disease. Mozaffari S, Nikfar S, Abdolghaffari AH, Abdollahi M. Expert Opin Biol Ther. 2014 May;14(5):583-600. doi: 10.1517/14712598.2014.885945. Epub 2014 Feb 6. Review.
 
10. A systematic review of the safety of probiotics. Didari T, Solki S, Mozaffari S, Nikfar S, Abdollahi M. Expert Opin Drug Saf. 2014 Feb;13(2):227-39. doi: 10.1517/14740338.2014.872627. Epub 2014 Jan 3. Review.
 
11. A Review on the Role of Oxidative Stress and Inflammation in Necrotizing Enterocolitis and Benefits of the Phosphodiesterase Inhibitor Pentoxifylline. Mozaffari S, Abdollahi M. International Journal of Pharmacology. 04/2013; 9(4):245-250. DOI: 10.3923/ijp.2013.245.250
 
12. Metabolic and toxicological considerations for the latest drugs used to treat irritable bowel syndrome. Mozaffari S, Nikfar S, Abdollahi M. Expert Opin Drug Metab Toxicol. 2013 Apr;9(4):403-21. doi: 10.1517/17425255.2013.759558. Epub 2013 Jan 19. Review.
 
13. Synergistic effect of probiotics, butyrate and L-Carnitine in treatment of IBD M Moeinian, SF Ghasemi-Niri, S Mozaffari, M Abdollahi. Journal of Medical Hypotheses and Ideas 7 (2), 50-53. 2013.
 
14. Benefit of Aloe vera and Matricaria recutita mixture in rat irritable bowel syndrome: Combination of antioxidant and spasmolytic effects. Asadi-Shahmirzadi A, Mozaffari S, Sanei Y, Baeeri M, Hajiaghaee R, Monsef-Esfahani HR, Abdollahi M. Chin J Integr Med. 2012 Dec 21. [Epub ahead of print]
 
15. Better Efficacy of Lactobacillus casei in Combination with Bifidobacterium bifidum or Saccharomyces boulardii in Recovery of Inflammatory Markers of Colitis in Rat. Seyedeh Farnaz Ghasemi-Niri , Sara Solki , Tina Didari , Shilan Mozaffari , Maryam Baeeri , Mohammad Amin Rezvanfar , Azadeh Mohammadirad , Hossein Jamalifar and Mohammad Abdollahi. Asian Journal of Animal and Veterinary Advances, 2012. ISSN 1683-9919 / DOI: 10.3923/ajava.2012.
16. The Mechanisms of Positive Effects of Melatonin in Dyslipidemia: A Systematic Review of Animal and Human Studies. Shilan Mozaffari , Shirin Hasani-Ranjbar and Mohammad Abdollahi. International Journal of Pharmacology, 2012. ISSN 1811-7775 / DOI: 10.3923/ijp.2012.
 
17. Melatonin, a promising supplement in inflammatory bowel disease: a comprehensive review of evidences. Mozaffari S, Abdollahi M. Curr Pharm Des. 2011 Dec;17(38):4372-8. Review.
 
18. Effects of Hypericum perforatum extract on rat irritable bowel syndrome. Mozaffari S, Esmaily H, Rahimi R, Baeeri M, Sanei Y, Asadi-Shahmirzadi A, Salehi-Surmaghi MH, Abdollahi M. Pharmacogn Mag. 2011 Jul;7(27):213-23. doi: 10.4103/0973-1296.84235.
 
19. Implications of melatonin therapy in irritable bowel syndrome: a systematic review. Mozaffari S, Rahimi R, Abdollahi M. Curr Pharm Des. 2010;16(33):3646-55. Review.
 
20. On the use of herbal medicines in management of inflammatory bowel diseases: a systematic review of animal and human studies. Rahimi R, Mozaffari S, Abdollahi M. Dig Dis Sci. 2009 Mar;54(3):471-80. doi: 10.1007/s10620-008-0368-x. Epub 2008 Jul 10. Review.